Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
MIRCERA®
(methoxy polyethylene glycol-epoetin beta) Injection
WARNINGS
ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS, AND TUMOR PROGRESSION OR RECURRENCE
Mircera, methoxy polyethylene glycol-epoetin beta, is an ESA which differs from erythropoietin through formation of a chemical bond between either the N-terminal amino group or the ε-amino group of any lysine present in erythropoietin, predominantly Lys52 and Lys45, and methoxy polyethylene glycol (PEG) butanoic acid (approximately 30,000 daltons). This results in a total molecular weight of approximately 60,000 daltons. Mircera is formulated as a sterile, preservative-free protein solution for intravenous or subcutaneous administration.
Injectable solutions of Mircera in prefilled syringes (30 mcg, 50 mcg, 75 mcg, 100 mcg, 120 mcg, 150 mcg, 200 mcg, or 250 mcg in 0.3 mL) are formulated in an aqueous solution containing mannitol (9 mg), methionine (0.447 mg), poloxamer 188 (0.03 mg), sodium phosphate monobasic monohydrate (0.414 mg), and sodium sulphate (1.704 mg). Mircera 360 mcg in 0.6 mL is formulated in an aqueous solution containing mannitol (18 mg), methionine (0.894 mg), poloxamer 188 (0.06 mg), sodium phosphate monobasic monohydrate (0.828 mg), and sodium sulphate (3.408 mg). The solution is clear, colorless to slightly yellowish and the pH is 6.2 ± 0.2.
Mircera is indicated for the treatment of anemia associated with chronic kidney disease (CKD) in:
Mircera is not indicated and is not recommended:
Mircera has not been shown to improve symptoms, physical functioning, or health-related quality of life.
Evaluate the iron status in all patients before and during treatment. Administer supplemental iron therapy when serum ferritin is less than 100 mcg/L or when serum transferrin saturation is less than 20%. The majority of patients with CKD will require supplemental iron during the course of ESA therapy.
Monitoring Of Response To Therapy
Correct or exclude other causes of anemia (e.g., vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding, etc.) before initiating Mircera [see WARNINGS AND PRECAUTIONS]. Following initiation of therapy and after each dose adjustment, monitor hemoglobin weekly until the hemoglobin level is stable and sufficient to minimize the need for RBC transfusion.
Individualize dosing and use the lowest dose of Mircera sufficient to reduce the need for RBC transfusions [see WARNINGS AND PRECAUTIONS]. In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL. No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Physicians and patients should weigh the possible benefits of decreasing transfusions against the increased risks of death and other serious cardiovascular adverse events [see BOXED WARNING and Clinical Studies].
When initiating or adjusting therapy, monitor hemoglobin levels at least weekly until stable, then monitor at least monthly. When adjusting therapy consider hemoglobin rate of rise, rate of decline, ESA responsiveness and hemoglobin variability. A single hemoglobin excursion may not require a dosing change.
Administer Mircera either intravenously or subcutaneously in adult patients and only intravenously in pediatric patients. When administered subcutaneously, Mircera should be injected in the abdomen, arm or thigh.
Refer patients who self-administer Mircera to the Instructions for Use [see PATIENT INFORMATION].
Conversion From Epoetin Alfa Or Darbepoetin Alfa To Mircera In Adult Patients With CKD
Mircera can be administered once every two weeks or once monthly to patients whose hemoglobin has been stabilized by treatment with an ESA (see Table 1). The dose of Mircera, given as a single intravenous or subcutaneous injection, should be based on the total weekly ESA dose at the time of conversion.
Table 1 : Mircera Starting Doses for Adult Patients
Currently Receiving an ESA
| Previous Weekly Epoetin alfa Dose (units/week) | Previous Weekly Darbepoetin alfa Dose (mcg/week) | Mircera Dose | |
| Once Monthly (mcg/month) | Once Every Two Weeks (mcg/every two weeks) | ||
| less than 8000 | less than 40 | 120 | 60 |
| 8000 to 16000 | 40 to 80 | 200 | 100 |
| more than 16000 | more than 80 | 360 | 180 |
Conversion From Epoetin Alfa Or Darbepoetin Alfa To Mircera In Pediatric Patients With CKD Treated With Hemodialysis
Administer Mircera intravenously once every 4 weeks to pediatric patients (ages 5 to 17 years) whose hemoglobin level has been stabilized by treatment with an ESA. Administer Mircera as an intravenous injection at the dose (in micrograms) based on the total weekly ESA dose at the time of conversion (see Table 2).
Table 2 : Mircera Starting Doses for Pediatric
Patients Currently Receiving an ESA
| Epoetin alfa | Darbepoetin alfa |
| 4 x previous weekly epoetin alfa dose (Units)/125 e.g., 4 x 1500 Units of epoetin alfa per week/125 = 48 mcg of Mircera once every 4 weeks | 4 x previous weekly darbepoetin alfa dose (mcg)/0.55 e.g., 4 x 20 mcg of darbepoetin alfa per week/0.55 = 145.5 mcg of Mircera once every 4 weeks |
Mircera is packaged as single-dose prefilled syringes. Mircera contains no preservatives. Discard any unused portion. Do not pool unused portions from the prefilled syringes. Do not use the prefilled syringe more than once.
Always store Mircera prefilled syringes in their original cartons. Vigorous shaking or prolonged exposure to light should be avoided.
Do not mix Mircera with any parenteral solution.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use any prefilled syringes exhibiting particulate matter or a coloration other than colorless to slightly yellowish.
For administration using the prefilled syringe, the plunger must be fully depressed during injection in order for the needle guard to activate. Following administration, remove the needle from the injection site and then release the plunger to allow the needle guard to move up until the entire needle is covered.
See “Instructions for Use” for complete instructions on the preparation and administration of Mircera. Examine each prefilled syringe for the expiration date. Do not use Mircera after the expiration date.
Injection: 30 mcg, 50 mcg, 75 mcg, 100 mcg, 120 mcg, 150 mcg, 200 mcg, or 250 mcg in 0.3 mL clear, colorless to slightly yellowish solution in single-dose prefilled syringes
Injection: 360 mcg in 0.6 mL clear, colorless to slightly yellowish solution in single-dose prefilled syringes
Mircera (methoxy polyethylene glycol-epoetin beta) injection is available in single-dose prefilled syringes. The syringe plungers are designated with unique colors for each dosage strength. The prefilled syringes are supplied with a 27 gauge, ½ inch needle. To reduce the risk of accidental needlesticks after application, each prefilled syringe is equipped with a needle guard that covers the needle during disposal.
Mircera is available in the following pack sizes:
Single-Dose Prefilled Syringe with a Needle Guard. A
27 Gauge, ½ inch Needle is also provided:
| One Prefilled Syringe/Pack | NDC number |
| 30 mcg/0.3 mL | NDC 59353-400-09 |
| 50 mcg/0.3 mL | NDC 59353-401-09 |
| 75 mcg/0.3 mL | NDC 59353-402-09 |
| 100 mcg/0.3 mL | NDC 59353-403-09 |
| 120 mcg/0.3 mL | NDC 59353-407-09 |
| 150 mcg/0.3 mL | NDC 59353-404-09 |
| 200 mcg/0.3 mL | NDC 59353-405-09 |
| 250 mcg/0.3 mL | NDC 59353-406-09 |
| 360 mcg/0.6 mL | NDC 59353-408-09 |
Store Mircera refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or shake.
The end-user may store the product at room temperature up to 25°C (77°F) in the original carton up to 30 days. Discard after 30 days.
Manufactured by: Vifor (International) Inc. Rechenstrasse 37 9014 St. Gallen Switzerland. Revised: Jun 2018
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
The data described below reflect exposure to Mircera in 2737 patients, including 1451 exposed for 6 months and 1144 exposed for greater than one year. Mircera was studied primarily in active-controlled studies (n=1789 received Mircera, and n=948 received another ESA) and in long-term follow up studies. The population was 18 to 92 years of age, 58% male, and the percentage of Caucasian, Black (including African Americans), Asian and Hispanic patients were 73%, 20%, 5%, and 9%, respectively. Approximately 85% of the patients were receiving dialysis. Most patients received Mircera using dosing regimens of once every two or four weeks, administered SC or IV.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of Mircera cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in practice.
The most commonly reported adverse reactions in ≥ 10% of patients were hypertension [see WARNINGS AND PRECAUTIONS], diarrhea, and nasopharyngitis. The most common adverse reactions that led to treatment discontinuation in the Mircera clinical studies were: hypertension, coronary artery disease, anemia, concomitant termination of other CKD therapy and septic shock. Some of the adverse reactions reported are typically associated with CKD, or recognized complications of dialysis, and may not necessarily be attributable to Mircera therapy. Adverse reaction rates did not importantly differ between patients receiving Mircera or another ESA.
Table 4 summarizes the most frequent adverse reactions ( ≥ 5%) in patients treated with Mircera.
Table 4 : Adverse Reactions Occurring in ≥ 5%
of CKD Patients
| Adverse Reaction | Patients Treated with Mircera (n=1789) |
| VASCULAR | |
| Hypertension | 13% |
| Hypotension | 5% |
| GASTROINTESTINAL | |
| Diarrhea | 11% |
| Vomiting | 6% |
| Constipation | 5% |
| INFECTIONS AND INFESTATIONS | |
| Nasopharyngitis | 11% |
| Upper Respiratory Tract Infection | 9% |
| Urinary Tract Infection | 5% |
| NERVOUS SYSTEM | |
| Headache | 9% |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE | |
| Muscle Spasms | 8% |
| Back Pain | 6% |
| Pain in Extremity | 5% |
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS | |
| Procedural Hypotension | 8% |
| Arteriovenous Fistula Thrombosis | 5% |
| Arteriovenous Fistula Site Complication | 5% |
| METABOLISM AND NUTRITION | |
| Fluid Overload | 7% |
| RESPIRATORY, THORACIC AND MEDIASTINAL | |
| Cough | 6% |
In the controlled trials, the rates of serious adverse reactions did not importantly differ between patients receiving Mircera and another ESA (38% vs. 42%) except for the occurrence of serious gastrointestinal hemorrhage (1.2% vs. 0.2%). Serious hemorrhagic adverse reactions of all types occurred among 5% and 4% of patients receiving Mircera or another ESA, respectively.
As with all therapeutic proteins, there is a potential for immunogenicity. Neutralizing antibodies to Mircera that cross-react with endogenous erythropoietin and other ESAs can result in PRCA or severe anemia (with or without other cytopenias) [see WARNINGS AND PRECAUTIONS]. Compared to SC administration, the IV route of administration may lessen the risk for development of antibodies to Mircera.
In 1789 patients treated with Mircera in clinical studies, antibody testing using an enzyme-linked immunosorbent assay (ELISA) was conducted at baseline and during treatment. Antibody development was not detected in any of the patients.
The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Mircera with the incidence of antibodies to other ESAs may be misleading.
The following adverse reactions have been identified during postapproval use of Mircera. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Stevens-Johnson syndrome/toxic epidermal necrolysis has been reported [see WARNINGS AND PRECAUTIONS].
Cases of PRCA and of severe anemia, with or without other cytopenias that arise following the development of neutralizing antibodies to erythropoietin have been reported in patients treated with Mircera [see WARNINGS AND PRECAUTIONS].
No formal drug/drug interaction studies have been performed.
Included as part of the PRECAUTIONS section.
The design and overall results of the 3 large trials comparing higher and lower hemoglobin targets are shown in Table 3 (Normal Hematocrit Study (NHS), Correction of Hemoglobin Outcomes in Renal Insufficiency (CHOIR) and Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT)).
Table 3 : Randomized Controlled Trials Showing Adverse
Cardiovascular Outcomes in Patients With CKD
| NHS (N = 1265) |
CHOIR (N = 1432) |
TREAT (N = 4038) |
|
| Time Period of Trial | 1993 to 1996 | 2003 to 2006 | 2004 to 2009 |
| Population | CKD patients on hemodialysis with coexisting CHF or CAD, hematocrit 30 ± 3% on epoetin alfa | CKD patients not on dialysis with hemoglobin less than 11 g/dL not previously administered epoetin alfa | CKD patients not on dialysis with type II diabetes, hemoglobin ≤ 11 g/dL |
| Hemoglobin Target; Higher vs. Lower (g/dL) | 14.0 vs. 10.0 | 13.5 vs. 11.3 | 13.0 vs. ≥ 9.0 |
| Median (Q1, Q3) Achieved Hemoglobin level (g/dL) | 12.6 (11.6, 13.3) vs. 10.3 (10.0, 10.7) | 13.0 (12.2, 13.4) vs. 11.4 (11.1, 11.6) | 12.5 (12.0, 12.8) vs. 10.6 (9.9, 11.3) |
| Primary Endpoint | All-cause mortality or nonfatal MI | All-cause mortality, MI, hospitalization for CHF, or stroke | All-cause mortality, MI, myocardial ischemia, heart failure, and stroke |
| Hazard Ratio or Relative Risk (95% CI) | 1.28 (1.06 to 1.56) | 1.34 (1.03 to 1.74) | 1.05 (0.94 to 1.17) |
| Adverse Outcome for Higher Target Group | All-cause mortality | All-cause mortality | Stroke |
| Hazard Ratio or Relative Risk (95% CI) | 1.27 (1.04 to 1.54) | 1.48 (0.97 to 2.27) | 1.92 (1.38 to 2.68) |
NHS: A prospective, randomized, open-label study of 1265 patients with chronic kidney disease on dialysis with documented evidence of congestive heart failure or ischemic heart disease was designed to test the hypothesis that a higher target hematocrit (Hct) would result in improved outcomes compared with a lower target Hct. In this study, patients were randomized to epoetin alfa treatment targeted to a maintenance hemoglobin of either 14 ± 1 g/dL or 10 ± 1 g/dL. The trial was terminated early with adverse safety findings of higher mortality in the high hematocrit target group. Higher mortality (35% vs. 29%) was observed for the patients randomized to a target hemoglobin of 14 g/dL than for the patients randomized to a target hemoglobin of 10 g/dL. For all-cause mortality, the HR=1.27; 95% CI (1.04, 1.54); p=0.018. The incidence of nonfatal myocardial infarction, vascular access thrombosis, and other thrombotic events was also higher in the group randomized to a target hemoglobin of 14 g/dL.
CHOIR: In a randomized prospective trial, 1432 patients with anemia due to CKD who were not undergoing dialysis were assigned to epoetin alfa treatment targeting a maintenance hemoglobin concentration of 13.5 g/dL or 11.3 g/dL. The trial was terminated early with adverse safety findings. A major cardiovascular event (death, myocardial infarction, stroke, or hospitalization for congestive heart failure) occurred among 125 (18%) of the 715 patients in the higher hemoglobin group compared to 97 (14%) among the 717 patients in the lower hemoglobin group (HR 1.3, 95% CI: 1.0, 1.7 p=0.03).
TREAT: A randomized, double-blind, placebo-controlled, prospective trial of 4038 patients with: CKD not on dialysis (eGFR of 20 – 60 mL/min), anemia (hemoglobin levels ≤ 11 g/dL), and type 2 diabetes mellitus, patients were randomized to receive either darbepoetin alfa treatment or a matching placebo. Placebo group patients also received darbepoetin alfa when their hemoglobin levels were below 9 g/dL. The trial objectives were to demonstrate the benefit of darbepoetin alfa treatment of the anemia to a target hemoglobin level of 13 g/dL, when compared to a “placebo” group, by reducing the occurrence of either of two primary endpoints: (1) a composite cardiovascular endpoint of all-cause mortality or a specified cardiovascular event (myocardial ischemia, CHF, MI, and CVA) or (2) a composite renal endpoint of all-cause mortality or progression to end stage renal disease. The overall risks for each of the two primary endpoints (the cardiovascular composite and the renal composite) were not reduced with darbepoetin alfa treatment (see Table 3), but the risk of stroke was increased nearly two-fold in the darbepoetin alfa-treated group versus the placebo group: annualized stroke rate 2.1% vs. 1.1%, respectively, HR 1.92; 95% CI: 1.38, 2.68; p less than 0.001. The relative risk of stroke was particularly high in patients with a prior stroke: annualized stroke rate 5.2% in the darbepoetin alfa-treated group and 1.9% in the placebo group, HR 3.07; 95% CI: 1.44, 6.54. Also, among darbepoetin alfa-treated subjects with a past history of cancer, there were more deaths due to all causes and more deaths adjudicated as due to cancer, in comparison with the control group.
An increased incidence of thromboembolic reactions, some serious and life-threatening, occurred in patients with cancer treated with ESAs.
In a randomized, placebo-controlled study (Study 1 in Table 4 [see Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients with Cancer] of 939 women with metastatic breast cancer receiving chemotherapy, patients received either weekly epoetin alfa or placebo for up to a year. This study was designed to show that survival was superior when epoetin alfa was administered to prevent anemia (maintain hemoglobin levels between 12 and 14 g/dL or hematocrit between 36% and 42%). This study was terminated prematurely when interim results demonstrated a higher mortality at 4 months (8.7% vs. 3.4%) and a higher rate of fatal thrombotic reactions (1.1% vs. 0.2%) in the first 4 months of the study among patients treated with epoetin alfa. Based on Kaplan-Meier estimates, at the time of study termination, the 12-month survival was lower in the epoetin alfa group than in the placebo group (70% vs. 76%; HR 1.37, 95% CI: 1.07, 1.75; p = 0.012).
Mircera is not approved for reduction of RBC transfusions in patients scheduled for surgical procedures.
An increased incidence of deep vein thrombosis (DVT) in patients receiving epoetin alfa undergoing surgical orthopedic procedures has been observed. In a randomized controlled study (referred to as the “SPINE” study), 681 adult patients, not receiving prophylactic anticoagulation and undergoing spinal surgery, received epoetin alfa and standard of care (SOC) treatment, or SOC treatment alone. Preliminary analysis showed a higher incidence of DVT, determined by either Color Flow Duplex Imaging or by clinical symptoms, in the epoetin alfa group [16 patients (4.7%)] compared to the SOC group [7 patients (2.1%)]. In addition, 12 patients in the epoetin alfa group and 7 patients in the SOC group had other thrombotic vascular events.
Increased mortality was observed in a randomized placebo-controlled study of epoetin alfa in adult patients who were undergoing coronary artery bypass surgery (7 deaths in 126 patients randomized to epoetin alfa versus no deaths among 56 patients receiving placebo). Four of these deaths occurred during the period of study drug administration and all four deaths were associated with thrombotic events.
Mircera is not indicated and is not recommended for use in the treatment of anemia due to cancer chemotherapy. A dose-ranging trial of Mircera in 153 patients who were undergoing chemotherapy for non- small cell lung cancer was terminated prematurely because more deaths occurred among patients receiving Mircera than another ESA.
ESAs resulted in decreased locoregional control/progression-free survival and/or overall survival (see Table 4). These findings were observed in studies of patients with advanced head and neck cancer receiving radiation therapy (Studies 5 and 6), in patients receiving chemotherapy for metastatic breast cancer (Study 1) or lymphoid malignancy (Study 2), and in patients with non-small cell lung cancer or various malignancies who were not receiving chemotherapy or radiotherapy (Studies 7 and 8).
Table 4 : Randomized, Controlled Trials with Decreased
Survival and/or Decreased Locoregional Control
| Study/Tumor (n) | Hemoglobin Target | Achieved Hemoglobin (Median Q1,Q3*) | Primary Endpoint | Adverse Outcome for ESA-containing Arm |
| Chemotherapy | ||||
| Cancer Study 1 Metastatic breast cancer (n=939) | 12 to 14 g/dL | 12.9 g/dL 12.2, 13.3 g/dL | 12-month overall survival | Decreased 12-month survival |
| Cancer Study 2 Lymphoid malignancy (n=344) | 13 to 15 g/dL (M) 13 to 14 g/dL (F) | 11.0 g/dL 9.8, 12.1 g/dL | Proportion of patients achieving a hemoglobin response | Decreased overall survival |
| Cancer Study 3 Early breast cancer (n=733) | 12.5 to 13 g/dL | 13.1 g/dL 12.5, 13.7 g/dL | Relapse-free and overall survival | Decreased 3-year relapse-free and overall survival |
| Cancer Study 4 Cervical cancer (n=114) | 12 to 14 g/dL | 12.7 g/dL 12.1, 13.3 g/dL | Progression-free and overall survival and locoregional control | Decreased 3-year progression-free and overall survival and locoregional control |
| Radiotherapy Alone | ||||
| Cancer Study 5 Head and neck cancer (n=351) | more than 15 g/dL (M) more than 14 g/dL (F) | Not available | Locoregional progression-free survival (LRPFS) | Decreased 5-year locoregional progression-free survival Decreased overall survival |
| Cancer Study 6 Head and neck cancer (n=522) | 14 to 15.5 g/dL | Not available | Locoregional disease control (LRC) | Decreased locoregional disease control |
| No Chemotherapy or Radiotherapy | ||||
| Cancer Study 7 Non-small cell lung cancer (n=70) | 12 to 14 g/dL | Not available | Quality of life | Decreased overall survival |
| Cancer Study 8 Non-myeloid malignancy (n=989) | 12 to 13 g/dL | 10.6 g/dL 9.4, 11.8 g/dL | RBC transfusions | Decreased overall survival |
| *Q1= 25th percentile; Q3= 75th percentile | ||||
Cancer Study 1 (the “BEST” study) was previously described [see Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism]. Mortality at 4 months (8.7% vs. 3.4%) was significantly higher in the epoetin alfa arm. The most common investigator-attributed cause of death within the first 4 months was disease progression; 28 of 41 deaths in the epoetin alfa arm and 13 of 16 deaths in the placebo arm were attributed to disease progression. Investigator assessed time to tumor progression was not different between the two groups. Survival at 12 months was significantly lower in the epoetin alfa arm (70% vs. 76%, HR 1.37, 95% CI: 1.07, 1.75; p=0.012).
Cancer Study 2 was a Phase 3, double-blind, randomized (darbepoetin alfa vs. placebo) study conducted in 344 anemic patients with lymphoid malignancy receiving chemotherapy. With a median follow-up of 29 months, overall mortality rates were significantly higher among patients randomized to darbepoetin alfa as compared to placebo (HR 1.36, 95% CI: 1.02, 1.82).
Cancer Study 7 was a Phase 3, multicenter, randomized (epoetin alfa vs. placebo), double-blind study, in which patients with advanced non-small cell lung cancer receiving only palliative radiotherapy or no active therapy were treated with epoetin alfa to achieve and maintain hemoglobin levels between 12 and 14 g/dL. Following an interim analysis of 70 of 300 patients planned, a significant difference in survival in favor of the patients on the placebo arm of the trial was observed (median survival 63 vs. 129 days; HR 1.84; p=0.04).
Cancer Study 8 was a Phase 3, double-blind, randomized (darbepoetin alfa vs. placebo), 16-week study in 989 anemic patients with active malignant disease, neither receiving nor planning to receive chemotherapy or radiation therapy. There was no evidence of a statistically significant reduction in proportion of patients receiving RBC transfusions. The median survival was shorter in the darbepoetin alfa treatment group (8 months) compared with the placebo group (10.8 months); HR 1.30, 95% CI: 1.07, 1.57.
Cancer Study 3 (the “PREPARE” study) was a randomized controlled study in which darbepoetin alfa was administered to prevent anemia conducted in 733 women receiving neo-adjuvant breast cancer treatment. A final analysis was performed after a median follow-up of approximately 3 years at which time the survival rate was lower (86% vs. 90%, HR 1.42, 95% CI: 0.93, 2.18) and relapse-free survival rate was lower (72% vs. 78%, HR 1.33, 95% CI: 0.99, 1.79) in the darbepoetin alfa-treated arm compared to the control arm.
Cancer Study 4 (protocol GOG 191) was a randomized controlled study that enrolled 114 of a planned 460 cervical cancer patients receiving chemotherapy and radiotherapy. Patients were randomized to receive epoetin alfa to maintain hemoglobin between 12 and 14 g/dL or to transfusion support as needed. The study was terminated prematurely due to an increase in thromboembolic events in epoetin alfa-treated patients compared to control (19% vs. 9%). Both local recurrence (21% vs. 20%) and distant recurrence (12% vs. 7%) were more frequent in epoetin alfa-treated patients compared to control. Progression-free survival at 3 years was lower in the epoetin alfa-treated group compared to control (59% vs. 62%, HR 1.06, 95% CI: 0.58, 1.91). Overall survival at 3 years was lower in the epoetin alfa-treated group compared to control (61% vs. 71%, HR 1.28, 95% CI: 0.68, 2.42).
Cancer Study 5 (the “ENHANCE” study) was a randomized controlled study in 351 head and neck cancer patients where epoetin beta or placebo was administered to achieve target hemoglobins of 14 and 15 g/dL for women and men, respectively. Locoregional progression-free survival was significantly shorter in patients receiving epoetin beta (HR 1.62, 95% CI: 1.22, 2.14, p=0.0008) with a median of 406 days epoetin beta vs. 745 days placebo. Overall survival was significantly shorter in patients receiving epoetin beta (HR 1.39, 95% CI: 1.05, 1.84; p=0.02).
Cancer Study 6 (DAHANCA 10) was conducted in 522 patients with primary squamous cell carcinoma of the head and neck receiving radiation therapy randomized to darbepoetin alfa with radiotherapy or radiotherapy alone. An interim analysis on 484 patients demonstrated that locoregional control at 5 years was significantly shorter in patients receiving darbepoetin alfa (RR 1.44, 95% CI: 1.06, 1.96; p=0.02). Overall survival was shorter in patients receiving darbepoetin alfa (RR 1.28, 95% CI: 0.98, 1.68; p=0.08).
Mircera is contraindicated in patients with uncontrolled hypertension.
In Mircera clinical studies, approximately 27% of patients with CKD, including patients on dialysis and patients not on dialysis, required intensification of antihypertensive therapy. Hypertensive encephalopathy and/or seizures have been observed in patients with CKD treated with Mircera [see Seizures].
Appropriately control hypertension prior to initiation of and during treatment with Mircera. Reduce or withhold Mircera if blood pressure becomes difficult to control. Advise patients of the importance of compliance with antihypertensive therapy and dietary restrictions [see PATIENT INFORMATION].
Seizures have occurred in patients participating in Mircera clinical studies. During the first several months following initiation of Mircera, monitor patients closely for premonitory neurologic symptoms. Advise patients to contact their healthcare practitioner for new-onset seizures, premonitory symptoms, or change in seizure frequency.
For lack or loss of hemoglobin response to Mircera, initiate a search for causative factors (e.g., iron deficiency, infection, inflammation, bleeding).
If typical causes of lack or loss of hemoglobin response are excluded, evaluate for PRCA [see Pure Red Cell Aplasia]. In the absence of PRCA, follow dosing recommendations for management of patients with an insufficient response to Mircera therapy [see DOSAGE AND ADMINISTRATION].
Cases of PRCA and of severe anemia, with or without other cytopenias that arise following the development of neutralizing antibodies to erythropoietin have been reported in the postmarketing setting in patients treated with Mircera. This has been reported predominantly in patients with CKD receiving ESAs by subcutaneous administration. PRCA was not observed in clinical studies of Mircera.
PRCA has also been reported in patients receiving ESAs for anemia related to hepatitis C treatment (an indication for which Mircera is not approved).
If severe anemia and low reticulocyte count develop during treatment with Mircera, withhold Mircera and evaluate patients for neutralizing antibodies to erythropoietin [see Lack or Loss of Hemoglobin Response to Mircera]. Serum samples should be obtained at least a month after the last Mircera administration to prevent interference of Mircera with the assay. Contact Vifor at 1-800-576-8295 to perform assays for binding and neutralizing antibodies. Permanently discontinue Mircera in patients who develop PRCA following treatment with Mircera or other erythropoietin protein drugs. Do not switch patients to other ESAs as antibodies may cross-react [see ADVERSE REACTIONS].
Serious allergic reactions, including anaphylactic reactions, angioedema, bronchospasm, tachycardia, pruritus skin rash and urticaria have been reported in patients treated with Mircera. If a serious allergic or anaphylactic reaction occurs due to Mircera, immediately and permanently discontinue Mircera and administer appropriate therapy.
Blistering and skin exfoliation reactions including Erythema multiforme and Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN), have been reported in patients treated with ESAs (including Mircera) in the postmarketing setting. Discontinue Mircera therapy immediately if a severe cutaneous reaction, such as SJS/TEN, is suspected.
Patients may require adjustments in their dialysis prescription after initiation of Mircera. Patients receiving Mircera may require increased anticoagulation with heparin to prevent clotting of the extracorporeal circuit during hemodialysis.
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Inform patients:
Administer Mircera under the direct supervision of a healthcare provider or, in situations where a patient has been trained to administer Mircera at home, provide instruction on the proper use of Mircera, including instructions to:
Always keep a puncture-proof disposal container available for the disposal of used syringes and needles.
No carcinogenicity or genotoxicity studies have been conducted with Mircera. Methoxy polyethylene glycolepoetin beta did not induce a proliferative response in either the erythropoietin receptor positive cell lines HepG2 and K562 or the erythropoietin receptor negative cell line RT112 in vitro. In addition, using a panel of human tissues, the in vitro binding of methoxy polyethylene glycol-epoetin beta was observed only in bone marrow progenitor cells.
When methoxy polyethylene glycol-epoetin beta was administered subcutaneously to male and female rats prior to and during mating, reproductive performance, fertility, and sperm assessment parameters were not affected.
Available data from a small number of published case reports and postmarketing experience with Mircera use in pregnancy are insufficient to identify a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Chronic kidney disease is associated with maternal and embryo-fetal risks (see Clinical Considerations). In animal reproduction studies, administration of methoxy polyethylene glycolepoetin beta to rats and rabbits during pregnancy and lactation adversely affected offspring at doses 17-fold and greater than the recommended human dose (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Disease Associated Maternal And/Or Embryo-Fetal Risk
Pregnancy in women with chronic kidney disease has been associated with adverse outcomes including hypertension, pre-eclampsia, miscarriage, premature birth, low-birth-weight, polyhydramnios, and intrauterine growth restriction.
When methoxy polyethylene glycol-epoetin beta was administered subcutaneously to rats and rabbits during gestation (including the period of organogenesis), bone malformation was observed in both species at 50 mcg/kg once every three days (corresponding to 500 mcg/kg/month or 417-fold the recommended human dose) in studies of embryo-fetal development. This effect was observed as missing caudal vertebrae resulting in a thread-like tail in one rat fetus, absent first digit metacarpal and phalanx on each forelimb resulting in absent pollex in one rabbit fetus, and fused fourth and fifth cervical vertebrae centra in another rabbit fetus. Dose-related reduction in fetal weights was observed in both rats and rabbits. At doses 5 mcg/kg once every three days and higher, corresponding to 50 mcg/kg/month or 42-fold the recommended human dose, methoxy polyethylene glycol-epoetin beta caused exaggerated pharmacodynamic effects in dams.
Once-weekly doses of methoxy polyethylene glycol-epoetin beta up to 50 mcg/kg/dose (corresponding to 200 mcg/kg/month or 167-fold the recommended human dose) given to pregnant and lactating rats did not adversely affect pregnancy parameters, natural delivery or litter observations in a study of pre-and postnatal development. Increased deaths and significant reduction in the growth rate of the F1 generation were observed during lactation and early post weaning period at 20 and 50 mcg/kg/dose, corresponding to 80 and 200 mcg/kg/month or 67- and 167-fold the recommended human dose. A significant reduction in the growth rate of the F1 generation was evident already at 5 mcg/kg/dose, corresponding to 20 mcg/kg/month or 17-fold the recommended human dose. However, no remarkable effect on reflex, physical and cognitive development or reproductive performance was observed in F1 generation of any dose groups.
The dose level not causing any adverse effect on dams or offspring was not determined.
There are no data on the presence of methoxy polyethylene glycol-epoetin beta in human milk, the effects on the breastfed child, or the effects on milk production. However, endogenous erythropoietin is present in human milk. In rats, methoxy polyethylene glycol-epoetin beta was present in maternal milk (see Data). When a drug is present in animal milk, it is likely that the drug will be present in human milk. The lack of clinical data during lactation precludes a clear determination of the risk of Mircera to a child during lactation. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Mircera and any potential adverse effects on the breastfed child from Mircera or from the underlying maternal condition.
Data
A dose of methoxy polyethylene glycol-epoetin beta approximately 3-fold greater than the recommended human dose was administered to lactating rats. Methoxy polyethylene glycol-epoetin beta was detected in maternal milk 4 hours postdose and reached maximum concentration 48 hours postdose. The maximum amount of methoxy polyethylene glycol-epoetin beta in milk was about 10-fold lower than in serum. The concentration of drug in animal milk does not necessarily predict the concentration of drug in human milk.
The safety and effectiveness of Mircera for the treatment of anemia due to CKD have been established in pediatric patients 5 to 17 years of age on hemodialysis who are converting from another ESA after their hemoglobin level was stabilized with an ESA. The use of Mircera in this pediatric age group is supported by evidence from adequate and well-controlled studies of Mircera in adults and a dose-finding study in 64 pediatric patients 5 to 17 years of age with CKD on hemodialysis. The adverse reaction profile observed in pediatric patients was consistent with the safety profile found in adults. The safety and effectiveness of Mircera have not been established in patients less than 5 years of age [see ADVERSE REACTIONS and Clinical Studies].
The safety and effectiveness of Mircera have not been established in pediatric patients of any age for subcutaneous administration; for treatment of anemia in patients with CKD on peritoneal dialysis; for treatment of anemia in patients with CKD who are not yet on dialysis; and for patients whose hemoglobin level has not been previously stabilized by treatment with an ESA.
Clinical studies of Mircera did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.
Mircera overdosage can elevate hemoglobin levels above the desired level, which should be managed with discontinuation or reduction of Mircera dosage and/or with phlebotomy, as clinically indicated [see Pharmacodynamics]. Cases of severe hypertension have been observed following overdose with ESAs [see WARNINGS AND PRECAUTIONS].
Mircera is contraindicated in patients with:
Mircera is an erythropoietin receptor activator with greater activity in vivo as well as increased half-life, in contrast to erythropoietin. A primary growth factor for erythroid development, erythropoietin is produced in the kidney and released into the bloodstream in response to hypoxia. In responding to hypoxia, erythropoietin interacts with erythroid progenitor cells to increase red cell production. Production of endogenous erythropoietin is impaired in patients with CKD and erythropoietin deficiency is the primary cause of their anemia.
Following a single-dose of Mircera in adult patients with CKD, the onset of hemoglobin increase (defined as an increase more than 0.4 g/dL from baseline) was observed 7 to 15 days following initial dose administration [see DOSAGE AND ADMINISTRATION].
The pharmacokinetics of methoxy polyethylene glycol-epoetin beta were studied in adult anemic patients with CKD including patients on dialysis and those not on dialysis. Parameters are presented as the geometric mean [% coefficient of variation (%CV)] unless otherwise specified.
Methoxy polyethylene glycol-epoetin beta did not accumulate following administration every four weeks. However, when Mircera was administered every 2 weeks, serum concentrations at steady state increased by 12%. Multiple dosing had no effect on clearance, volume of distribution or bioavailability of methoxy polyethylene glycol-epoetin beta.
Following the subcutaneous administration of Mircera, the maximum serum concentrations of methoxy polyethylene glycol-epoetin beta were observed at a median [min, max] time of 72 [24, 192] hours. The absolute bioavailability of Mircera after the subcutaneous administration was 62%.
The volume of distribution at steady state was 61 [46%] mL/kg.
Following an intravenous administration of Mircera 0.4 mcg/kg body weight to patients with CKD receiving peritoneal dialysis, the observed terminal half-life was 119 [55%] hours, and the total systemic clearance was 0.47 [35%] mL/hr/kg. Following a subcutaneous administration of Mircera 0.8 mcg/kg to CKD patients receiving peritoneal dialysis, the terminal half-life was 124 [57%] hours.
The pharmacokinetics of methoxy polyethylene glycol-epoetin beta were not altered by age (range: 6 to 89 years), gender, race, severe hepatic impairment (Child-Pugh Class C), site of subcutaneous injection (abdomen, arm or thigh), or the use of dialysis.
The pharmacokinetics of methoxy polyethylene glycol-epoetin beta were studied in 64 pediatric patients with CKD (ages 5 to 17 years) who were on hemodialysis and who were previously receiving another ESA (epoetin alfa/beta or darbepoetin alfa). At steady state (following the third intravenous administration of Mircera), the observed Cmax was 66 [150%] ng/mL, and the AUC0-tau was 7170 [140%] ng.hr/mL in the group who were dosed using the recommended conversion factor [see DOSAGE AND ADMINISTRATION]. Methoxy polyethylene glycol-epoetin beta serum concentrations declined with an apparent half-life of 121 [44%] hours, and a total systemic clearance of 0.51 [96%] mL/hr/kg.
In early clinical studies conducted in CKD patients on dialysis, ESAs have been shown to reduce the use of RBC transfusions. These studies enrolled patients with mean baseline hemoglobin levels of approximately 7.5 g/dL and ESAs were generally titrated to achieve a hemoglobin level of approximately 12 g/dL. Fewer transfusions were given during the ESA treatment period when compared to a pre-treatment interval.
In NHS, the yearly transfusion rate was 51.5% in the lower hemoglobin group (10 g/dL) and 32.4% in the higher hemoglobin group (14 g/dL).
In TREAT, a randomized, double-blind trial of 4038 patients with CKD and type 2 diabetes not on dialysis, a post-hoc analysis showed that the proportion of patients receiving RBC transfusions was lower in patients administered an ESA to target a hemoglobin of 13 g/dL compared to the control arm in which the ESA was administered intermittently if hemoglobin concentration decreased to less than 9 g/dL (15% versus 25%, respectively). In CHOIR, a randomized open-label study of 1432 patients with CKD not on dialysis, use of an ESA to target a higher (13.5 g/dL) versus lower (11.3 g/dL) hemoglobin goal did not reduce the use of RBC transfusions. In each trial, no benefits occurred for the cardiovascular or end-stage renal disease outcomes. In each trial, the potential benefit of ESA therapy was offset by worse cardiovascular safety outcomes resulting in an unfavorable benefit-risk profile [see WARNINGS AND PRECAUTIONS].
Mircera use has not been demonstrated in controlled clinical trials to improve quality of life, fatigue, or patient well-being.
Three randomized outcome trials (NHS, CHOIR and TREAT) have been conducted in patients with CKD using Epogen/PROCRIT/Aranesp to target higher vs. lower hemoglobin levels. Though these trials were designed to establish a cardiovascular or renal benefit of targeting higher hemoglobin levels, in all 3 studies, patients randomized to the higher hemoglobin target experienced worse cardiovascular outcomes and showed no reduction in progression to ESRD. In each trial, the potential benefit of ESA therapy was offset by worse cardiovascular safety outcomes resulting in an unfavorable benefit-risk profile [see WARNINGS AND PRECAUTIONS].
The efficacy and safety of Mircera were assessed in six open-label, multi-center clinical studies that randomized patients to either Mircera or a comparator ESA. Two studies evaluated anemic patients with CKD who were not treated with an ESA at baseline and four studies evaluated patients who were receiving an ESA for treatment of the anemia of CKD. In all studies, patients were assessed as clinically stable at baseline and without evidence of infection or inflammation as determined by history and laboratory data, including C-reactive protein (CRP ≤ 15 mg/L for study 1 and CRP ≤ 30 mg/L for studies 2 to 6). A CRP value above the threshold led to the exclusion of no more than 3% of the screened patients.
In the clinical studies, ESAs were administered to achieve specific hemoglobin levels (see Table 6 and Table 7). Following stabilization of hemoglobin levels (12 g/dL), the median monthly Mircera dose was 150 mcg (range of 97 mcg to 270 mcg).
Patients Not Currently Treated With An ESA
In Study 1 patients who were not receiving dialysis were randomized to Mircera or darbepoetin alfa, administered for 28 weeks. The starting dose of Mircera was 0.6 mcg/kg administered subcutaneously once every two weeks and the starting dose of darbepoetin alfa was 0.45 mcg/kg administered subcutaneously once a week. In Study 2, patients who were receiving dialysis were randomized to Mircera or another ESA (epoetin alfa or epoetin beta), administered for 24 weeks. The starting dose of Mircera was 0.4 mcg/kg administered intravenously once every two weeks and the starting dose of the comparator was administered intravenously three times a week, consistent with the product's recommended dose. In these studies, the observed median dose of Mircera once every two weeks over the course of the correction/evaluation period was 0.6 mcg/kg. Table 6 provides the results of the two studies.
Table 6 : Clinical Studies in Patients Not Currently
Treated with an ESA
| Group (n) | Percent Achieving Goal* (95% CI) | Mean Hemoglobin Change from Baseline (g/dL) | RBC Transfusion, % |
| Study 1 | |||
| Mircera (n=162) | 98 (94, 99) | 2.1 | 2.5 |
| Darbepoetin alfa (n=162) | 96 (92, 99) | 2.0 | 6.8 |
| Study 2 | |||
| Mircera (n=135) | 93 (88, 97) | 2.7 | 5.2 |
| Epoetin alfa/beta (n=46) | 91 (79, 98) | 2.6 | 4.3 |
| *Goal: hemoglobin increase of at least 1 g/dL and to a level of at least 11 g/dL without RBC transfusion; hemoglobin levels were to be maintained within the range of 11 to 13 g/dL. | |||
Patients Currently Treated With An ESA
Four studies assessed the ability of Mircera to maintain hemoglobin levels among patients currently treated with other ESAs. Patients were randomized to receive Mircera administrations either once every two weeks or once every four weeks, or to continue their current ESA dose and schedule. The initial Mircera dose was determined based on the patient's previous weekly ESA dose. As shown in Table 7, treatment with Mircera once every two weeks and once every four weeks maintained hemoglobin levels within the targeted hemoglobin range (10 to 13.5 g/dL).
Table 7 : Clinical Studies in Patients Currently
Treated with an ESA
| Group (n) | Mean Baseline Hemoglobin | Evaluation Period Hemoglobin (Mean) | Between-group Difference *, g/dL (95% or 97.5% CI) |
| Study 3 | |||
| Mircera intravenously every 2 weeks (n=223) | 12.0 | 11.9 | 0.0 (-0.2, 0.2) |
| Mircera intravenously every 4 weeks (n=224) | 11.9 | 11.9 | 0.1 (-0.2, 0.3) |
| Epoetin alfa/beta intravenously (n=226) | 12.0 | 11.9 | n/a |
| Study 4 | |||
| Mircera subcutaneously every 2 weeks (n=190) | 11.7 | 11.7 | 0.1 (-0.1, 0.4) |
| Mircera subcutaneously every 4 weeks (n=191) | 11.6 | 11.5 | -0.0 (-0.3, 0.2) |
| Epoetin beta subcutaneously (n=191) | 11.6 | 11.5 | n/a |
| Study 5 | |||
| Mircera intravenously every 2 weeks (n=157) | 12.0 | 12.1 | 0.2 (-0.0, 0.4) |
| Darbepoetin alfa intravenously (n=156) | 11.9 | 11.8 | n/a |
| Study 6 | |||
| Mircera intravenously/ subcutaneously every 2 weeks (n=168) | 11.8 | 11.9 | 0.1 (-0.1, 0.4) |
| Epoetin alfa intravenously/ subcutaneously (n=168) | 11.9 | 11.9 | n/a |
| *Mircera versus comparator mean hemoglobin difference in
the evaluation period 97.5% CI are shown for studies that compared two Mircera
groups to another ESA (Studies 3 and 4) and 95% CI are shown for the other
studies. n/a = not applicable Data are from the per-protocol (primary analysis) population, numbers indicate total patients randomized. |
|||
An open-label, multiple dose, multicenter, dose-finding study (NCT00717366) was conducted to determine the dose of intravenous Mircera when converting from treatment with another ESA (epoetin alfa/beta or darbepoetin alfa). The study was conducted in 64 pediatric patients (ages 5 to 17 years) with CKD who were on hemodialysis and who had stable hemoglobin (Hb) levels while previously receiving another ESA. Eligible patients were administered Mircera intravenously once every 4 weeks for 20 weeks. After the first administration of Mircera, dosage adjustments were permitted to maintain target Hb levels.
Efficacy was established based on the change in Hb concentration (g/dL) between the baseline and evaluation periods. Of the two conversion factors studied, the recommended conversion factor for Mircera [see DOSAGE AND ADMINISTRATION] was confirmed based on patients maintaining Hb within target levels. Among the 48 patients who received Mircera dosed using the recommended conversion factor, 9 patients withdrew due to renal transplant, 2 patients withdrew due to administrative reasons, 1 died, and 1 patient refused treatment. One of the 13 patients who withdrew from the study entered the evaluation period (weeks 17 to 21). For the 36 patients who entered the evaluation period and received the dose of Mircera calculated using the recommended conversion factor, the mean change in Hb concentration from baseline between the baseline and the evaluation period was -0.15 g/dL with 95% CI (-0.49, 0.2).
Supportive efficacy results in the group treated with Mircera using the recommended conversion factor demonstrated that 75% of patients maintained Hb values within ± 1 g/dL of baseline and 81% maintained Hb values within 10 to 12 g/dL during the evaluation period. Dose decreases and increases were reported in 38% of patients.
MIRCERA®
(mir-SER-ah)
(methoxy polyethylene glycol-epoetin beta)
Read this Medication Guide:
This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or your treatment. Talk with your healthcare provider regularly about the use of Mircera and ask if there is new information about Mircera.
What is the most important information I should know about Mircera?
Mircera may cause serious side effects that can lead to death, including:
For people with cancer: Mircera is not for use to treat anemia that is caused by cancer chemotherapy. If you have certain cancers, your tumor may grow faster and you may die sooner if you take Mircera.
See “What are the possible side effects of Mircera?” below for more information.
If you decide to take Mircera, your healthcare provider should prescribe the smallest dose of Mircera that is necessary to reduce your chance of needing red blood cell transfusions.
What is Mircera?
Mircera is a prescription medicine used to treat anemia. People with anemia have a lower-thanÂnormal number of RBCs. Mircera works like the human protein called erythropoietin to help your body make more RBCs. Mircera is used to reduce or avoid the need for RBC transfusion.
Mircera may be used to treat anemia if it is caused by chronic kidney disease (you may or may not be on dialysis).
If your hemoglobin level stays too high or if your hemoglobin goes up too quickly, this may lead to serious health problems which may result in death. These serious health problems may happen if you take Mircera, even if you do not have an increase in your hemoglobin level. Mircera is not for use for the treatment of anemia:
Mircera has not been proven to improve the quality of life, fatigue, or well-being.
It is not known if Mircera is safe and effective in children.
Who should not take Mircera?
Do not take Mircera if you:
What should I tell my healthcare provider before taking Mircera?
Mircera may not be right for you. Tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of your medicines with you and show it to your healthcare provider when you get a new medicine.
How should I take Mircera?
What are possible side effects of Mircera?
Mircera may cause serious side effects.
Common side effects of Mircera include:
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all of the possible side effects of Mircera. Your healthcare provider can give you a more complete list. Tell your healthcare provider about any side effects that bother you or that do not go away.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1Â800-FDA-1088.
How should I store Mircera?
Keep Mircera and all medicines out of the reach of children.
General information about Mircera
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Mircera for a condition for which it was not prescribed. Do not give Mircera to other people, even if they have the same symptoms that you have. It may harm them.
This Medication Guide summarizes the most important information about Mircera. If you would like more information about Mircera, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about Mircera that is written for health professionals.
What are the ingredients in Mircera?
Active ingredient: methoxy polyethylene glycol-epoetin beta
Inactive ingredients: sodium phosphate, sodium sulphate, mannitol, methionine and poloxamer 188
Instructions for Use
MIRCERA®
(mir-SER-ah)
(methoxy polyethylene glycol-epoetin beta) Injection Single-Dose
Prefilled Syringe
Read the Medication Guide that comes with Mircera for the most important information you need to know. The following instructions explain how to give yourself or another individual an injection of Mircera using the single-dose prefilled syringe. Be sure that you read, understand and follow these instructions before injecting a dose of Mircera so that you are able to use the prefilled syringe correctly and safely. Your healthcare provider should show you how to correctly prepare and inject Mircera using the single-dose prefilled syringe before you use it for the first time. Ask your healthcare provider or pharmacist if you have any questions about Mircera.
When you receive your Mircera prefilled syringes, make sure that:
Important Information:
Storage
How should I store Mircera?
Keep Mircera and all medicines out of the reach of children.
Materials
Materials included in the Mircera prefilled syringe pack (Figure A):
Figure A
 |
Materials not included in the Mircera prefilled syringe pack (Figure B):
Figure B
 |
Important: Follow these instructions exactly to help avoid infections.
Preparing for an injection:
1. Gather all of the materials you will need for an injection on a clean, well-lit, flat work surface such as a table.
2. Allow the syringe to reach room temperature: Carefully remove your prescribed pack of Mircera from the refrigerator (see Figure C).
Figure C
 |
Do not warm up the prefilled syringe in any other way.
3. Open the pack and remove the plastic tray containing the Mircera prefilled syringe without peeling back the protective film (see Figure D).
Figure D
 |
4. Wash your hands well with soap and warm water (see Figure E).
Figure E
 |
5. Remove and inspect the prefilled syringe. Open the plastic tray by peeling back the protective film. Remove the prefilled syringe by holding the syringe by the device body (see Figure F). Do not touch the release clips.
Figure F
 |
6. Inspect the medicine and prefilled syringe (see Figure G.).
Do not use the prefilled syringe if:
Figure G
 |
Attach needle to prefilled syringe:
7. Grab the prefilled syringe by the finger grips. Carefully pull the rubber tip cap away from the prefilled syringe. It may require a strong bend and pull to remove it (see Figure H).
Figure H
 |
Place the syringe on your work surface. Be careful that the tip of the prefilled syringe does not touch anything. If the tip of the syringe touches anything, dispose of the prefilled syringe (see “Disposing of used prefilled syringes and needles” below) and use a new prefilled syringe and needle for the injection.
8. Grab the packaged needle firmly in both hands. Break the seal of the needle, using a twisting motion, and remove the plastic needle cap (see Figure I).
Figure I
 |
9. Attach the needle to the prefilled syringe by pushing it firmly onto the prefilled syringe (see Figure J).
Figure J
 |
10. Put the prefilled syringe on its side with the needle shield on. This will keep the needle from touching anything before you use it.
Follow your healthcare provider's instructions for how you should inject Mircera.
Subcutaneous (under the skin) injection:
If your healthcare provider tells you to inject Mircera under your skin, give your dose as described below:
Selecting and preparing a subcutaneous injection site:
11. Choose an injection site as shown in Figure K. The three sites where you can inject Mircera include:
Choose a new injection site each time you inject Mircera, at least 1-inch from the area you used for the previous injection. This helps to avoid soreness at any one site.
Figure K
 |
Do not inject Mircera into moles or into an area of your body that is tender, red, bruised, hard, or that has scars or stretch marks, or is not intact.
Do not inject into areas that could be irritated by a belt or waistband.
12. Clean the injection site with an alcohol swab (see Figure L).
Do not fan or blow on the clean area.
Figure L
 |
13. Hold the syringe firmly with one hand and pull off the needle shield with the other hand (see Figure M). Throw away the needle shield in the sharps disposal container.
Figure M
 |
14. Check the prefilled syringe for air bubbles. To remove air bubbles from the prefilled syringe, hold the syringe by the body with the needle pointing up. Tap the syringe gently to bring the air bubbles to the top (see Figure N).
Figure N
 |
15. Push the plunger up gently and slowly until you see a drop of liquid coming out of the needle (see Figure O).
Figure O
 |
16. Find a comfortable position to give an injection of Mircera.
Hold the prefilled syringe in the hand that you will use to inject Mircera. Use the other hand to pinch a fold of loose skin at the cleaned injection site (see Figure P).
Figure P
 |
17. Hold the prefilled syringe like a pencil. Fully and carefully insert the needle into the skin in a quick “dartÂlike” motion. Insert straight up and down (90 degree angle) into the skin. Keep the syringe in the skin and slowly let go of the pinch of skin.
Slowly push the plunger with your thumb all the way down while holding the syringe with the forefinger and the middle finger against the finger grips until all the medicine is injected (see Figure Q). The plastic needle guard (a safety guard to prevent accidental needle sticks) will not move forward to cover the needle unless the full dose is given.
Figure Q
 |
18. Take the needle out of the skin without releasing the plunger (see Figure R).
Figure R
 |
19. Release the plunger after removing the needle from the skin. This will allow the syringe to move back until the entire needle is covered with the needle guard (see Figure S).
Figure S
 |
20. Now the tear-off label can be removed, if necessary to keep a record of the dose taken (see Figure T).
Figure T
 |
21. After the injection: Place a sterile cotton ball or gauze over the injection site and press for several seconds (see Figure U).
If needed, you may cover the injection site with a small adhesive bandage.
Figure U
 |
22. Dispose of the used prefilled syringe: Throw away (dispose of) the used prefilled syringe and the attached needle in the sharps container right away. Do not reuse your prefilled syringe or needle. See “Disposing of used prefilled syringes and needles” below.
Intravenous (IV) injection:
Injecting a dose of Mircera for people on hemodialysis using intravenous injection:
After you prepare the syringe as described in steps 7 to 10 above:
Clean the venous port of the hemodialysis tubing with an alcohol swab (see Figure A).
Figure A
 |
2. Hold the syringe firmly with one hand and pull off the needle shield with the other hand (see Figure B). Throw away the needle shield in the sharps disposal container.
Figure B
 |
3. Check the prefilled syringe for air bubbles. To remove air bubbles from the prefilled syringe, hold the syringe by the device body with the needle pointing up. Tap the syringe gently to bring the air bubbles to the top (see Figure C).
Figure C
 |
4. Push the plunger up gently and slowly until you see a drop of liquid coming out of the needle (see Figure D).
Figure D
 |
5. Insert the needle on the prefilled syringe into the cleaned venous port (see Figure E).
Figure E
 |
6. Push the plunger with your thumb all the way down, while holding the syringe with the forefinger and the middle finger against the finger grips until all the medicine is injected (see Figure F). Pull back on the syringe and remove the needle from the venous port without releasing the plunger.
Figure F
 |
The plastic needle guard (a safety guard to prevent accidental needle sticks) will not move forward to cover the needle unless the full dose is given (see Figure G).
Figure G
 |
Release the plunger after removing the needle from the port. This will allow the syringe to move back until the entire needle is covered with the needle guard (see Figure G).
7. Now the tear-off label can be removed, if necessary to keep a record of the dose taken (see Figure H).
Figure H
 |
8. Dispose of the used prefilled syringe: Throw away (dispose of) the used prefilled syringe and the attached needle in the sharps container right away. Do not reuse your prefilled syringe and needle. See “Disposing of used prefilled syringes and needles” below.
Disposing of used prefilled syringes and needles:
Always keep the sharps disposal container out of the reach of children.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
